Epidermolysis Bullosa Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Epidermolysis Bullosa Treatment Market is segmented By Treatment Type (Medication, Wound Care, Others) By Condition Type (Epidermolysis Bullosa Simplex, Dystrophic Epidermolysis Bullosa, Kindler Syndrome, Epidermolysis Bullosa Acquisita) By Distribution Channel (Hospital Pharmacies, Community & Local Pharmacies, Online Pharmacies) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Market Size

The global epidermolysis bullosa therapeutics market reached US$ 1.96 billion in 2023 and is expected to reach US$ 3.35 billion by 2031, growing at a CAGR of 7.0% during the forecast period 2024-2031.

Epidermolysis bullosa is a rare disorder causing fragile, blistering skin, often seen in newborns or young children. It is inherited and has no cure, but treatment focuses on healing existing blisters and preventing new ones. There are several types of epidermolysis bullosa which include Epidermolysis bullosa simplex, a skin condition affecting the outer layer of skin, mainly affecting the palms and feet. It can be severe, causing hoarse-sounding crying and scarring of vocal cords. Dystrophic epidermolysis bullosa is related to a gene flaw, causing thin skin and constipation. Kindler syndrome causes blisters in multiple layers, causing thin, mottled, and wrinkly skin. Epidermolysis bullosa acquisita is rare and has no cure. Treatment focuses on healing existing blisters and preventing new ones. Recently novel therapuetic options are under investigation which are focusing on repairing the mutated genes.

Market Summary

For more details on this report - Request for Sample

Market Dynamics

Rise in product innovations and launches

The treatment of epidermolysis bullosa majorly focuses on symptomatic relief and preventative measures to avoid complications. There is no cure currently available for epidermolysis bullosa and the treatment option include healing the wounds, managing the pain, providing nutritional support, physical therapy, surgical interventions etc. Due to its inherant nature, genetic abnormilities play a crucial role in the disease predisposition. 

Currently with the advent of technology in understading the etiology of this rare disease, several preclinical and clinical studies were being conducted focusing on a new avenue of epidermolysis bullosa treatment. Several innovative gene therapies, cell therapies are being currently investigated under several phases of clinical trials some of which have recently gained the commercialization approval by the FDA. There novel therapies are expected to pave a new path for the treatment of epidermolysis bullosa and is expected to drive the market growth in the forecast period.

For instance, on May 19, 2023, U.S. Food and Drug Administration has approved the first ever gene therapy for the treatment of epidermolysis bullosa. The topical gene therapy Vyjuvek developed by Krystal Biotech is currently marketed in U.S. and is being prescribed for six month and older patients with dystrophic epidermolysis bullosa (DEB).

On December 19, 2023, FILSUVEZ a topical gel for the treatment of Junctional Epidermolysis Bullosa (JEB) and Dystrophic Epidermolysis Bullosa (DEB) developed by Chiesi Group received U.S. Food and Drug Administration approval for use in 6 month and older patients. FISUVEZ has already received approval from European Commission in 2022 for the same indication.

In October 2023, RHEACELL GmbH & Co. KG has initiated phase III clinical trial for its innovative allogeneic ABCB5-positive dermal mesenchymal stromal cells for treatment of epidermolysis bullosa. The company aims to finish the trials by the end of 2025. The same therapy had recently got market approval for use in chronic venous wounds. 

Moreover, growing investment in orphan drug development, advancements in wound care technologies are expected to drive the market growth.

Restraints

Factors such as limited treatment modalities, Limited number of patient population are expected to restrain the market growth. As epidermolysis bullosa is very rare, the population with the condition is very small, which limits the incentive by manufacturers to invest in therapy development. Moreover, it is difficult to conduct clinical trials with a limited population as the recruitment get difficult and the outcome cannot be significantly quantified.

Market Segment Analysis

The global epidermolysis bullosa treatment market is segmented based on product type, condition type, distribution channel, and region.

The epidermolysis bullosa simplex in the condition type segment accounted for approximately 43.2% of the global epidermolysis bullosa treatment market share

Epidermolysis bullosa is a very rare condition with approximately 500,000 cases worldwide. Epidermolysis bullosa is a plethora term used for refer various types of conditions classified on the basis of blister morpohology, severity and genetic mutation involved etc. Among these conditions, epidermolysis bullosa simplex (EBS) is the most common form in which the blistering is seen on the uppermost layer of the skin epidermis. In EBS, the genes encoding keratin production are mutated whose role is to provide strutural integrity to the skin. Most of the patients with epidermolysis bullosa have epidermolysis bullosa simplex (EBS).

For instance, on Jaunary 11, 2024, according to an article published in the National Center for Biotechnology Information has stated that epidermolysis bullosa simplex is the most common form accounting for approximately 70% of total cases globally. The other forms such as junctional epidermolysis bullosa accouts for 5% of the cases, dystrophic epidermolysis bullosa accounts for 25% of the cases, and kindler syndrome accounts is a very rare form with only 400 

Market Geographical Share

North America is expected to dominate the market with 44.7% share in the global epidermolysis bullosa treatment market

North America is expected to dominate the market due to its advanced healthcare system. A major healthcare hub in North America, the U.S. is a leading country in the world with highest percapita healthcare spending. 

For instance, on January 03, 2024, an article published by  PETER G. PETERSON FOUNDATION stated that U.S. has the highest per-capita helathcare spending of $13,493 which is far more higher than any other developed country in the world. This is majorly due to higher prices of healthcare services and introduction of new and inovative technologies in healthcare industry. 

Although the prevalance of epidermolysis bullosa is lower in U.S. than other countries, the higher cost of treatment is expected to play a major role in contributing to the greater market share for North America.

The treatment of epidermolysis bullosa majorly involves wound care. North America has the highest spending on the woundcare as compared to any other developed nation which is the major factor contributing to the higher market share for North America

For instance, on January 21, 2024, an article published in the National Center for Biotechnology Information has reported the estimated cost of wound care among top countries worldwide. The U.S. has the highest expenditure for woundcare in 2022 with 148.65 billion $PPP (Purchasing Power Parity), followed by the second top country China with only 42.78 billion $PPP. A huge difference can be seen on the expenditure made by U.S. for wound care.

Moreover, with favourable reimubursement scenario, easy availability of healthcare facilities to the american citizens are other factors playing a key role for the highest market share in U.S.

Market Key Players

The major players in the epidermolysis bullosa treatment market include Krystal Biotech, Inc., CHIESI Farmaceutici S.p.A., Abigo Medical, Convatec Inc., GSK plc., Smith+Nephew, Johnson & Johnson Consumer Inc., URGO MEDICAL., Mölnlycke Health Care AB, and Medline Industries, LP. among others. 

COVID-19 Impact Analysis

The global market for epidermolysis bullosa treatment was affected by the COVID-19 pandemic. The pandemic has led to disruptions in healthcare services including dermatological care for epidermolysis bullosa patients. The face-to-face visits were greatly affected by imposed restrictions on movement and travel. This has led to disruption in the continuous access to healthcare services. Apart from this, the adoption of telemedicine has somewhat helped to address the medical needs of epidermolysis bullosa patients. But, due lack of facilities in low-middle-income countries the patients living in those areas are greatly affected.

For instance, on January 17, 2022, an article published in the National Center for Biotechnology Information has stated that many practices focusing on wound care have faced a significant reduction in patient volume and the mode of care has shifted more towards virtual platforms. The practice of self and home-based care has risen during the pandemic. 

Why Purchase the Report?

• To visualize the global epidermolysis bullosa treatment market segmentation based on treatment type, condition type, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of epidermolysis bullosa treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global epidermolysis bullosa treatment market report would provide approximately 62 tables, 53 figures, and 187 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies